| Literature DB >> 32154676 |
Francesca Puledda1,2, Dominic Ffytche3, David J Lythgoe4, Owen O'Daly4, Christoph Schankin5, Steven C R Williams4, Peter J Goadsby1,2.
Abstract
OBJECTIVE: To investigate the pathophysiology of visual snow (VS), through a combined functional neuroimaging and magnetic resonance spectroscopy (1 H-MRS) approach.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32154676 PMCID: PMC7086005 DOI: 10.1002/acn3.50986
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Figure 1An image of the visual snow simulation video used for the fMRI experiment.
Demographic and clinical characteristics of the VS patient group (n = 24).
| Gender, Age | Age of VS onset | Type of visual static | Presence of additional visual symptoms | MIG | Concomitant medication | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | T | BF | FL | SL | FLA | NY | PH | |||||
| F, 33 | # | BW,C,F,T | √ | √ | √ | √ | √ | √ | √ | √ | √ | Multivitamins |
| M, 28 | 10 | C | √ | √ | ||||||||
| M, 29 | 26 | BW | √ | √ | √ | √ | √ | √ | √ | Levothyroxine, paracetamol PRN | ||
| M, 25 | 19 | BW,F,T | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
| F, 20 | # | BW,T | √ | √ | √ | √ | √ | √ | √ | Fexofenadine | ||
| M, 31 | 9 | BW,F | √ | √ | √ | √ | √ | Pimecrolimus topical, betamethasone topical | ||||
| F, 34 | # | BW,C,F | √ | √ | √ | √ | √ | √ | ||||
| F, 23 | # | BW,C | √ | √ | √ | √ | √ | √ | √ | Oral contraceptive | ||
| F, 21 | # | BW,F,T | √ | √ | √ | √ | √ | √ | √ | √ | √ | Paracetamol PRN |
| M, 27 | 21 | BW | √ | √ | √ | √ | √ | √ | √ | |||
| F, 26 | 26 | BW | √ | √ | √ | √ | √ | √ | √ | √ | Multivitamins, ibuprofen PRN | |
| F, 43 | 43 | BW,F,T | √ | √ | √ | √ | √ | |||||
| F, 34 | 12 | BW | √ | √ | √ | √ | √ | √ | √ | |||
| F, 22 | # | T | √ | √ | √ | √ | √ | √ | Multivitamins, Paracetamol, Nexplanon | |||
| F, 34 | 31 | BW,T | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
| M, 22 | 15 | F,T | √ | √ | √ | √ | ||||||
| F, 25 | # | T | √ | √ | √ | √ | √ | √ | Salbutamol inhaler, multivitamins | |||
| F, 26 | 25 | BW,C,F,T | √ | √ | √ | √ | √ | √ | √ | √ | Paracetamol PRN | |
| M, 22 | 17 | F | √ | √ | √ | √ | √ | √ | Magnesium | |||
| M, 31 | 24 | BW | √ | √ | √ | √ | √ | √ | √ | √ | Paracetamol PRN | |
| M, 35 | 33 | BW | √ | √ | √ | √ | √ | √ | √ | √ | Levothyroxine, CQ10 | |
| M, 19 | # | BW | √ | √ | ||||||||
| M, 29 | # | F,T | √ | √ | √ | √ | ||||||
| M, 30 | # | BW,F | √ | √ | √ | √ | √ | √ | √ | √ | Fluticasone nasal spray | |
#, symptoms present for as long as patient could recall; BW, black and white static; C, coloured static; F, flashing static; T, transparent static; √, symptom reported; A, Afterimages; T, Trailing; BF, blue‐field entoptic phenomena; FL, floaters; SL, self‐light of the eye; FLA, flashes; NY, nyctalopia; PH, Photophobia; MIG, Migraine diagnosis; PRN, pro re nata (i.e. when necessary).
Figure 2Areas of increased (red/yellow) and decreased (blue/green) BOLD signal in patients (A) and controls (B) when subject to visual ‘snow‐like’ stimulus, respect to baseline. Bars represent T values.
Brain areas of differential BOLD response to visual stimulus respect to baseline, in patients and controls.
| Group | Contrast | Brain region |
|
| T | Peak coordinates | ||
|---|---|---|---|---|---|---|---|---|
| Cluster description |
|
|
| |||||
| Patients | Activation | Bilateral primary and secondary visual cortices, LG, fusiform gyrus, BA 17‐18‐19 | 8370 | <0.001 | 13.01 | 10 | −92 | −6 |
| Patients | Deactivation | Bilateral periventricular areas, cuneus, precuneus, LG | 3862 | <0.001 | 7.73 | 20 | −38 | 14 |
| R middle frontal gyrus, R superior frontal gyrus, FEF, BA 8‐9‐10 | 1013 | <0.001 | 5.66 | 34 | 38 | 28 | ||
| L precentral and L post central gyrus, BA 4‐7‐31 | 297 | 0.024 | 4.96 | −24 | −28 | 36 | ||
| R frontal operculum, R inferior frontal gyrus, R insula, BA 13‐22 | 685 | <0.001 | 4.91 | 50 | 10 | 0 | ||
| R supramarginal gyrus, R inferior parietal lobule, BA 40‐2 | 288 | 0.027 | 4.75 | 56 | −42 | 44 | ||
| Controls | Activation | Bilateral primary and secondary visual cortices, lingual and fusiform gyrus, BA 17‐18‐19 | 7942 | <0.001 | 15.87 | 18 | −96 | −8 |
| L precentral gyrus, L inferior frontal gyrus, BA 45‐6 | 304 | 0.003 | 5.67 | −56 | 10 | 40 | ||
| Controls | Deactivation | Bilateral periventricular areas, cuneus, precuneus, LG | 6075 | <0.001 | 12.02 | −24 | −50 | 8 |
| L postcentral gyrus | 921 | <0.001 | 4.66 | −20 | −32 | 54 | ||
Cluster coordinates are shown in MNI space with relative T scores and k values. An initial voxel threshold of P < 0.001 and cluster correction to P < 0.05 was applied. R, right; L, left; LG, lingual gyrus; FEF, frontal eye fields; BA, Brodmann area.
Figure 3Analysis for BOLD group differences in patients versus controls, in response to visual stimulation (i.e. ‘snow‐like’ stimulus) with respect to baseline. Plots for effects of group for the respective clusters are shown on the lower panel. Bars represent T‐values. (A) Whole brain analysis showing a reduction of BOLD signal in VS patients in the left anterior insula (k = 291; P = 0.025; peak MNI coordinates: x = −34, y = 12, z = −6). (B) SVC with anatomical mask over the right anterior insula, showing a significant reduction of BOLD signal in VS patients (k = 100; P = 0.003; peak MNI coordinates: x = 44, y = 14, z = −2).
Figure 4Magnetic resonance spectroscopy results. (A) Example of voxel placement in the right lingual gyrus and (B) example spectrum in one subject. (C) Average metabolite concentrations in visual snow patients versus controls. *Represents significant differences (P < 0.001; obtained with Mann‐Whitney U test).
Figure 5(A) Average BOLD responses in the right lingual gyrus, in VS patients versus controls (−0.29 vs. 0.03; P < 0.001). (B) Correlation between lactate concentrations and BOLD beta values in the right lingual gyrus (P = 0.004; r = −0.42).